| Variables | NCDB Long Term Outcomes | MIS Converted to open, N = 8451 | p-value2 | |
|---|---|---|---|---|
| Overall, N = 4,8351 | MIS, N = 3,9901 | |||
| Age | 64.00 (55.00, 73.00) | 64.00 (55.00, 72.00) | 65.00 (57.00, 73.00) | 0.003 |
| Sex | <0.001 | |||
| Female | 2,420 (50%) | 2,046 (51%) | 374 (44%) | |
| Male | 2,415 (50%) | 1,944 (49%) | 471 (56%) | |
| Race | 0.42 | |||
| Black | 507 (10%) | 429 (11%) | 78 (9.2%) | |
| Other | 298 (6.2%) | 246 (6.2%) | 52 (6.2%) | |
| White | 4,030 (83%) | 3,315 (83%) | 715 (85%) | |
| Insurance Status | 0.061 | |||
| Medicaid | 244 (5.0%) | 199 (5.0%) | 45 (5.3%) | |
| Medicare | 2,294 (47%) | 1,858 (47%) | 436 (52%) | |
| Not Insured | 78 (1.6%) | 68 (1.7%) | 10 (1.2%) | |
| Private Insurance/Managed Care/Goverment | 2,178 (45%) | 1,832 (46%) | 346 (41%) | |
| Unknown | 41 (0.8%) | 33 (0.8%) | 8 (0.9%) | |
| Region | 0.26 | |||
| Midwest | 1,120 (25%) | 900 (24%) | 220 (27%) | |
| NorthEast | 1,273 (28%) | 1,055 (28%) | 218 (27%) | |
| South | 1,543 (34%) | 1,282 (34%) | 261 (32%) | |
| West | 631 (14%) | 514 (14%) | 117 (14%) | |
| Unknown | 268 | 239 | 29 | |
| Income | 0.010 | |||
| < $38,000 | 670 (14%) | 564 (14%) | 106 (13%) | |
| >=$63,000 | 1,881 (39%) | 1,586 (40%) | 295 (35%) | |
| $38,000-$47,999 | 1,005 (21%) | 810 (20%) | 195 (23%) | |
| $48,000-$62,999 | 1,271 (26%) | 1,024 (26%) | 247 (29%) | |
| Unknown | 8 | 6 | 2 | |
| No High School Degree | 0.40 | |||
| <7.0% | 1,426 (30%) | 1,197 (30%) | 229 (27%) | |
| >=21.0% | 653 (14%) | 535 (13%) | 118 (14%) | |
| 13.0-20.9% | 1,090 (23%) | 889 (22%) | 201 (24%) | |
| 7.0-12.9% | 1,659 (34%) | 1,364 (34%) | 295 (35%) | |
| Unknown | 7 | 5 | 2 | |
| Population | 0.14 | |||
| Metro | 4,047 (86%) | 3,347 (86%) | 700 (86%) | |
| Rural | 35 (0.7%) | 33 (0.8%) | 2 (0.2%) | |
| Urban | 619 (13%) | 504 (13%) | 115 (14%) | |
| Unknown | 134 | 106 | 28 | |
| Charlson-Deyo Disability Score | <0.001 | |||
| >=3 | 168 (3.5%) | 129 (3.2%) | 39 (4.6%) | |
| 0 | 3,120 (65%) | 2,628 (66%) | 492 (58%) | |
| 1 | 1,248 (26%) | 1,000 (25%) | 248 (29%) | |
| 2 | 299 (6.2%) | 233 (5.8%) | 66 (7.8%) | |
| Staging | <0.001 | |||
| Stage 0 | 186 (4.1%) | 158 (4.2%) | 28 (3.6%) | |
| Stage I | 2,186 (48%) | 1,897 (50%) | 289 (37%) | |
| Stage II | 2,143 (47%) | 1,693 (45%) | 450 (57%) | |
| Stage III | 48 (1.1%) | 29 (0.8%) | 19 (2.4%) | |
| Unknown | 272 | 213 | 59 | |
| Tumor Grade | <0.001 | |||
| Moderately differentiated | 1,428 (30%) | 1,138 (29%) | 290 (34%) | |
| Poorly differentiated | 645 (13%) | 490 (12%) | 155 (18%) | |
| Undifferentiated | 65 (1.3%) | 46 (1.2%) | 19 (2.2%) | |
| Unknown | 633 (13%) | 531 (13%) | 102 (12%) | |
| Well differentiated | 2,064 (43%) | 1,785 (45%) | 279 (33%) | |
| Median Survival | 27.33 (14.72, 44.12) | 27.83 (15.46, 44.49) | 23.99 (11.76, 41.97) | <0.001 |
| Unknown | 1,006 | 839 | 167 | |
| Vital Status | <0.001 | |||
| Alive | 2,682 (70%) | 2,296 (73%) | 386 (57%) | |
| Dead | 1,147 (30%) | 855 (27%) | 292 (43%) | |
| Unknown | 1,006 | 839 | 167 | |
|
1
Statistics presented: Median (IQR); n (%)
2
Statistical tests performed: Wilcoxon rank-sum test; chi-square test of independence
|
||||